Home › Peripheral T-Cell Lymphoma
Peripheral T-Cell Lymphoma clinical trials recruiting in the U.S.
20 studies for Peripheral T-Cell Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX9 studies
- New York City, NY6 studies
- Baldwin Park, CA5 studies
- Boston, MA5 studies
- Philadelphia, PA4 studies
- Aurora, CO3 studies
- Ann Arbor, MI3 studies
- Columbus, OH3 studies
- Atlanta, GA3 studies
By state
- California8 studies
- Colorado3 studies
- Florida4 studies
- Georgia3 studies
- Maryland3 studies
- Massachusetts5 studies
- Michigan5 studies
- New Jersey3 studies
- New York7 studies
- Ohio5 studies
- Pennsylvania6 studies
- Texas10 studies
Recently updated studies
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06630091Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06561048CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RecruitingPhase 2
Ages 18 to 99 · All sexes · Updated Sep 24, 2026 · NCT04083495A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07195916AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 14, 2026 · NCT06137144A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 24, 2026 · NCT07055477A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07192471Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
RecruitingEarly phase 1
Ages 1 to 31 · All sexes · Updated Aug 18, 2026 · NCT03719105Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07750886A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Recruiting
Ages 18 and older · All sexes · Updated Jul 27, 2026 · NCT04045470To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT06072131Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Jul 20, 2026 · NCT06176690Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06508463Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT04068597Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05313243Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Jun 4, 2026 · NCT06131801Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT07356245Amping up With PemJAK
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Dec 16, 2025 · NCT07283822Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2025 · NCT04234048Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 6, 2025 · NCT03964480From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.